Jurcic J G
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Cancer Biother Radiopharm. 2000 Aug;15(4):319-26. doi: 10.1089/cbr.2000.15.319.
Monoclonal antibodies (mAbs) have become an important modality for cancer therapy. A genetically engineered, humanized anti-CD33 antibody HuM195 has demonstrated activity against over relapsed acute myelogenous leukemia (AML) and against minimal residual disease in acute promyelocytic leukemia (APL). Radioimmunotherapy with beta (beta) particle-emitting isotopes has produced significant responses while minimizing radiation exposure to normal tissues in both nonmyeloablative and myeloablative regimens. Targeted alpha (alpha) particle therapy with 213Bi-labeled HuM195 offers the possibility of more selective tumor cell kill. Additionally, directed chemotherapy using an anti-CD33-calicheamicin conjugate (CMA-676) has produced remissions in patients with relapsed AML.
单克隆抗体（mAb）已成为癌症治疗的一种重要方式。一种基因工程人源化抗CD33抗体HuM195已显示出对复发急性髓性白血病（AML）以及急性早幼粒细胞白血病（APL）微小残留病的活性。在非清髓性和清髓性方案中，使用发射β粒子的同位素进行放射免疫治疗已产生显著反应，同时将对正常组织的辐射暴露降至最低。用213Bi标记的HuM195进行靶向α粒子治疗提供了更具选择性地杀死肿瘤细胞的可能性。此外，使用抗CD33-卡奇霉素缀合物（CMA-676）进行定向化疗已使复发AML患者获得缓解。
